AMPA Receptor Antagonists in Neurodegenerative Disease

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Antagonists in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Talampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Topiramate</td>
<td>AD</td>
</tr>
</table>

Overview

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Antagonists in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Talampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Topiramate</td>
<td>AD</td>
</tr>
</table>

Overview

AMPA receptor (AMPAR) antagonists are a class of drugs that block alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are ionotropic glutamate receptors responsible for fast excitatory neurotransmission in the central nervous system. In neurodegenerative diseases, excessive AMPA receptor activation contributes to excitotoxicity through calcium influx and subsequent cellular dysfunction. AMPAR antagonists provide neuroprotection by reducing excitotoxic damage. [@ampa]

AMPA Receptors in Neurodegeneration

Role in Normal Synaptic Transmission

• AMPA receptors mediate the majority of fast excitatory neurotransmission in the brain
• GluA1-4 subunits form functional receptors (flip/flop splice variants)
• Calcium permeability depends on GluA2 subunit editing (Q/R site)
• Receptor trafficking underlies [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and depression (LTD)

Pathological Activation in Disease

Alzheimer's Disease: [@excitotoxicity]

• [Aβ](/proteins/amyloid-beta) oligomers enhance AMPA receptor surface expression
• Dysregulated calcium homeostasis through AMPAR
• Synaptic depression and spine loss via overactivation
• Impaired [LTP](/mechanisms/long-term-potentiation) and enhanced LTD

• Subthalamic nucleus (STN) hyperactivity increases glutamatergic output
• Excitotoxicity contributes to dopaminergic neuron loss
• Motor [cortex](/brain-regions/cortex) hyperexcitability in PD

• GluA2 subunit downregulation increases calcium permeability
• Excitatory amino acid transporter (EAAT) dysfunction
• Enhanced susceptibility to glutamate toxicity

• Mutant [huntingtin](/proteins/huntingtin-protein) alters AMPAR trafficking
• Enhanced excitotoxicity in striatal medium spiny [neurons](/entities/neurons)
• Altered synaptic plasticity

Pharmacological Agents

Perampanel (Fycompa)

Mechanism: Non-competitive AMPA receptor antagonist; binds to the GluA2/3 subunits [@calciumpermeable]

Clinical approvals: [@glua]

• FDA/EMA approved for epilepsy (partial-onset seizures)
• Investigated for neurodegenerative diseases

• Reduces excitotoxic damage in preclinical models
• Being evaluated in Phase II trials for PD
• May improve motor function in dyskinesias

• CNS side effects (dizziness, somnolence)
• Potential for psychiatric effects

Talampanel

Mechanism: Non-competitive AMPA antagonist

Clinical trials:

• Phase II trial in ALS: Showed slow disease progression
• Well-tolerated in patients
• No significant survival benefit in initial trial

LY-466365

Mechanism: Selective AMPA receptor antagonist

Development: Advanced to Phase II trials for ALS Outcome: Did not meet primary efficacy endpoints

Selfotel

Mechanism: Competitive AMPA receptor antagonist

Clinical trials:

• Studied in stroke and traumatic brain injury
• Too low therapeutic window
• Did not advance for neurodegeneration

Topiramate

Mechanism: Multiple mechanisms including AMPA receptor antagonism

Clinical use: Antiepileptic Neuroprotective potential:

• Reduces excitotoxicity
• Being investigated in AD models

Novel AMPA Modulators

Lyrica (Pregabalin)

Mechanism: Binds to α2δ subunit of voltage-gated calcium channels (not direct AMPAR) Neuroprotective effects: Indirectly reduces glutamate release

Therapeutic Strategies

Gene Therapy Approaches

• GluA2 editing: Viral delivery of ADAR enzymes to increase Q/R editing
• RNAi targeting GluA1: Reduce expression of calcium-permeable AMPARs

Combination Therapy

AMPAR antagonists are being combined with:

• [NMDA](/entities/nmda-receptor) receptor modulators: Broader excitotoxicity coverage
• Neurotrophic factors: GDNF, BDNF
• Antioxidants: CoQ10, vitamin E
• Anti-aggregants: Target upstream pathology

Clinical Trial Status

Biomarkers for Patient Selection

• GluA2 expression: Lower GluA2 = more calcium permeable = better target
• CSF glutamate levels: Elevated glutamate predicts response
• Genetic variants: GRIA2 polymorphisms may affect drug response

Adverse Effects

Common Side Effects

• Dizziness
• Somnolence
• Headache
• Nausea
• Fatigue

Psychiatric Effects (Perampanel)

• Irritability
• Aggression
• Mood changes
• Rare: Suicidal ideation

Future Directions

• Disease-specific formulations: Targeting specific neurodegenerative conditions
• Peripheral targeting: Avoiding CNS side effects
• Positive allosteric modulators: Enhancing beneficial signaling
• Subunit-selective compounds: Targeting specific AMPAR subunits

See Also

• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Calcium Dysregulation Pathway](/mechanisms/calcium-dysregulation-pathway)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [ALS Therapeutics](/therapeutics/als-therapeutics)
• [Parkinson's Disease Treatments](/therapeutics/parkinsons-disease-treatments)
• [NMDA Receptor Antagonists](/therapeutics/nmda-receptor-antagonists)

Clinical Significance

Research on this gene has revealed important insights into neurodegenerative disease mechanisms and therapeutic targets.

Disease Mechanisms

• Understanding how gene variants contribute to disease pathogenesis
• Protein dysfunction and aggregation pathways
• Impact on neuronal survival and function
• Interactions with other disease-related proteins

Therapeutic Implications

• Identification of novel drug targets
• Development of targeted therapies
• Biomarker development for diagnosis and progression
• Gene therapy and CRISPR-based approaches

Research Directions

• Ongoing clinical studies and trials
• Biomarker validation studies
• Natural history studies
• Translational research initiatives

Background

The study of Ampa Receptor Antagonists In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

• [ClinicalTrials.gov - AMPA antagonists](https://clinicaltrials.gov/)
• [ALS Association - Drug Development](https://www.als.org/)
• [Parkinson's Foundation - Clinical Trials](https://www.parkinson.org/)
• [Society for Neuroscience - Glutamate Receptors](https://www.sfn.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1

Related Analyses:

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;